New England Has $7.6 Billion Worth of Reasons to Embrace the Pharmaceutical-Biotech Industry
New England Has $7.6 Billion Worth of Reasons to Embrace the Pharmaceutical-Biotech Industry
Attachment: lifescience
SUGAR LAND--July 20, 2016--Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--New England has long been a favorite of the Pharmaceutical-Biotech Industry, hosting an impressive roster of the top biotech and pharmaceutical companies, along with nascent but promising start-ups. The region's attractions include formidable intellectual capacity and strong governmental support. A recent analysis of Industrial Info's Pharmaceutical-Biotech Industry database revealed $7.6 billion in active reported projects in New England. Within this article: Details of Pfizer's (NYSE:PFE) pharma-bio project in Andover, Massachusetts.
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- Make Sure to RSVP for Industrial Info's Mid-Year North American Outlook
- Pharma-Bio Third-Quarter 2016 Update: $5.8 Billion Investment in Project St...
- Life Science Sector Bets Big on Bay State: $5.5 billion Active CAPEX Facili...
- Medical Devices & Equipment Sector Brings Billions in Spending to the U.S.
- Double Vision: Jacobs Ready to Spin Off Government Services